12:45 - 13:00 Opening ceremony

13:00 - 14:30 SCIENTIFIC SESSION

Genetics of ALL-Subtypes

Chair: JM Ribera (Spain)

• Counting chromosomes in 2018: Is aneuploidy relevant in the genomic era?
  A Moorman (United Kingdom)
• MLL rearranged ALL
  R Pieters (The Netherlands)
• BCR-ABL like ALLs
  S Chiaretti (Italy)

Pitch presentations

• 1.1 Multiomics of relapsed B-Cell precursor Acute Lymphoblastic Leukemia
  CDB Baldus (Germany)
• 1.2 The mutational and transcriptome landscape of infant B-cell acute lymphoblastic leukemia: The INTERFANT treatment protocol experience
  AAD Agraz-Doblas (Spain)
• 1.3 A novel subgroup of B cell precursor ALL defined by PAX5 sequence variants cooperating with CDKN2A deletions and RAS activating mutations
  LB Bastian (Germany)
• 1.4 Amplicon-based NGS as a tool for the identification of new poor prognosis markers B-ALL
  AMB Montaño (Spain)

14:30 - 15:30 SCIENTIFIC SESSION

Personalised medicine in ALL

Chair: R Bassan (Italy)

• Molecular approach
  C Mullighan (USA)
• Drug response profiling for hematologic malignancies
  JP Bourquin (Switzerland)

Pitch presentations

• 2.1 Circular RNAs as novel therapeutic targets in drug resistant childhood leukemia
  UF Fischer (Germany)
• 2.2 Advanced diagnostic approach in the new AIEOP protocol for Acute Lymphoblastic Leukemia
  GC Cazzaniga (Italy)

15:30 - 16:00 Coffee break & Poster viewing

16:00 - 17:30 SCIENTIFIC SESSION

Management of BCR-ABL+ ALL

Chair: N Gökbuget (Germany)

• Management of BCR-ABL+ ALL - Diagnosis
  S Chiaretti (Italy)
• Treatment landscape for Ph+ALL: How to select options
  O Ottmann (United Kingdom)
• Practical management
  P Rousselot (France)

Pitch presentations

• 3.1 Enhancing management of Philadelphia-Positive (Ph+) ALL by monitoring with an analytically validated multiplex assay for BCR-ABL1 minor breakpoint (e1a2) with highly sensitive detection of 1:40,000 (0.0025% or 4.6 Logs)
  JTB Brown (USA)
• 3.2 Long term analysis of a randomized study comparing prophylactic and MRDtriggered, pre-emptive imatinib after SCT for Ph+/BCR-ABL1 positive ALL
  HP Pfeifer (Germany)

17:45 - 18:45 HARMONY PROJECTS

HARMONY: a European network of excellence for big data in hematology

Chair: N Gökbuget (Germany)

• Overview of HARMONY: Healthcare alliance for resourceful medicine offensive against neoplasms in hematology
  F Cerisoli (The Netherlands)
• Hematologic malignancies Big Data in HARMONY: the ALL experience
  A Moorman (United Kingdom)

17:45 - 18:45 MEET-THE-EXPERT

Technical aspects of MRD assessment in ALL - pitfalls and challenges for correct clinical interpretation

Chair: JM Ribera (Spain)

• Expert: M Brüggemann (Germany)

17:45 - 18:45 MEET-THE-EXPERT

De-escalation of treatment in pediatric ALL

Chair: R Bassan (Italy)

• Expert: M Schrappe (Germany)

18:45 - 19:45 Welcome reception & Poster session

07:15 - 08:45 EARLY BIRD WORKSHOP A (not included in the registration fee)

Optimal management of relapsed ALL

Chair: D Hoelzer (Germany)

• Speaker: A Fielding (United Kingdom)

07:15 - 08:45 EARLY BIRD WORKSHOP B (not included in the registration fee)

Algorithms for detection of BCR-ABL like ALL

Chair: R Foà (Italy)

• Speaker: C Mullighan (USA)

Pitch presentations

• W1 Workflow for prospective screening of BCR-ABL1-like genetic alterations in ALL in the GRAALL-2014 trial
  EC Clappier (France)
• W2 Custom targeted RNA sequencing for the classification of BCR-ABL1-like acute lymphoblastic leukemia and the identification of druggable mutations and fusions
  TH Herold (Germany)
• W3 Frequency of ABL-class fusions and gene rearrangements activating JAK-STAT signalling in 331 adults with 'B-other' acute lymphoblastic leukaemia enrolled on the UKALL14 and 60+ trials
  T Creasey (United Kingdom)

09:00 - 10:30 SCIENTIFIC SESSION

Minimal residual disease in ALL

Chair: H Dombret (France)

• MRD quantification in ALL - will NGS be the new standard?
  M Brüggemann (Germany)
• Prognostic and therapeutic impact of MRD in adult ALL
  N Gökbuget (Germany)
• Prognostic and therapeutic role of MRD in pediatric acute lymphoblastic leukemia (ALL)
  M Schrappe (Germany)

Pitch presentation

• 4.1 Molecular profile refines the MRD-based prognostic assessment in adults with Philadelphia negative B-cell precursor acute lymphoblastic leukemia
  JRS Ribera (Spain)

10:30 - 11:00 Coffee break & Poster viewing

11:00 - 12:30 SCIENTIFIC SESSION

Targeted immunotherapy - Recent data

Chair: N Gökbuget (Germany)

• Bispecifics
  M Topp (Germany)
• The use of monoclonal antibodies in the treatment of acute lymphoblastic leukemia
  D DeAngelo (USA)
• CAR-T-cells
  F Locatelli (Italy)

Pitch presentations

• 5.1 Planned and current immunotherapy trials from the French-Belgian-Swiss Group for Research on Adult ALL (GRAALL)
  HD Dombret (France)
• 5.2 GIMEMA trials with Blinatumomab in Ph- negative and Ph-positive ALL
  SC Chiaretti (Italy) & RB Bassan (Italy)
• 5.3 Ongoing and planned immunotherapy trials from the European study groups. The Spanish PETHEMA Group
  JMR Ribera (Spain)
• 5.4 Planned and current immunotherapy trials from the German Multicenter Study Group for Adult ALL (GMALL)
  N Gökbuget (Germany)
• 5.5 Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults
  CS Salek (Czech Republic)
• 5.6 CART19-BE-01: a pilot trial on the use of a ARI-0001 cells (i.e. CART19 cells transduced with a new construct comprising A3B1:CD8:4-1BB:CD3z) in patients with CD19+ relapsed/refractory acute lymphoid leukemia
  J Delgado (Spain)

12:30 - 14:00 Lunch & Poster viewing

13:00 - 14:00 SATELLITE SYMPOSIUM

ALL Insights: current challenges and future opportunities in the 1st-line treatment of adults with ALL

• Welcome & introductions
  S Giebel (Poland)
• Current strategies to effectively treat adult and AYA patients with ALL in the 1st-line setting
  R Foà (Italy)
• Toxicity management in the 1st-line ALL treatment setting
  D Hoelzer (Germany)
• Looking ahead - clinically meaningful future directions in 1st-line ALL treatment
  S Giebel (Poland)

14:00 - 15:00 ROUND TABLE

How to realize individualised treatment in ALL

Chair: D Hoelzer (Germany)

• D DeAngelo (USA)
• O Ottmann (United Kingdom)
• JP Bourquin (Switzerland)
• A Fielding (United Kingdom)
• N Gökbuget (Germany)
• H Dombret (France)
• M Schrappe (Germany)
• R Pieters (The Netherlands)

15:00 - 16:30 SCIENTIFIC SESSION

T-ALL - The forgotten subtype?

Chair: D Hoelzer (Germany)

• Biology of T-ALL and options for targeted therapy
  C Mullighan (USA)
• T-ALL in adults: Another success story (to be continued)
  R Bassan (Italy)
• Management of lymphoblastic lymphoma
  H Dombret (France)

Pitch presentations

• 7.1 Methylation clusters in adult T-ALL reveal distinct molecular characteristics
  MN Neumann (Germany)
• 7.2 CI-FISH: a powerful tool for the genetic diagnosis of T-ALL to improve precise diagnosis and address new treatments
  RLS La Starza (Italy)
• 7.3 Characteristics and outcome of the early T cell precursor ALL (ETP-ALL) patients treated with high-risk protocols from the Spanish PETHEMA Group
  EGF Genesca (Spain)
• 7.4 PTEN alterations predict poor outcome in children with T-cell acute lymphoblastic leukemia treated according to I-BFM protocols
  BSZ Szarzyńska-Zawadzka (Poland)
• 7.5 Adoptive cellular immunotherapy using CD1a CART-cells for treatment of cortical pediatric T-Cell Acute Lymphoblastic Leukemia
  DSM Sanchez Martinez (Spain)

16:30 - 17:00 Coffee break & Poster viewing

17:00 - 18:15 SCIENTIFIC SESSION

Standard drugs in ALL - Practical handling

Chair: S Giebel (Poland)

• Benefits and risks of intensifying asparaginase dosing in adult ALL. Can we identify patients who are most at risk?
  A Fielding (United Kingdom)
• Maintenance therapy - Facts and fiction
  K Schmiegelow (Denmark)
• Late effects and optimal aftercare
  R Pieters (The Netherlands)

Pitch presentations

• 8.1 The differential effects of chemotherapy on the Acute Lymphoblastic Leukaemia microenvironment suggests a possible mechanism for maintenance chemotherapy
  RJB Burt (United Kingdom)
• 8.2 Therapy-related acute lymphoblastic leukemia has distinct clinical and pathologic features compared to de novo acute lymphoblastic leukemia
  IA Aldoss (USA)

07:45 - 08:45 MEET-THE-EXPERT

Management of adverse events - Immunotherapies

Chair: F Locatelli (Italy)

• Expert: M Topp (Germany)

07:45 - 08:45 MEET-THE-EXPERT

Challenges in stem cell transplantation

Chair: D Hoelzer (Germany)

• Expert: S Giebel (Poland)

09:00 - 11:00 SCIENTIFIC SESSION

Standard therapy of de novo ALL

Chair: R Bassan (Italy)

• Overview of younger adults
  N Gökbuget (Germany)
• New opportunities for treatment of older adults with ALL
  JM Ribera (Spain)
• Treatment of childhood acute lymphoblastic leukemia
  K Schmiegelow (Denmark)
• Short presentations
  Planned and ongoing trials of adult National Study Groups

Pitch presentations

• 9.1 Standard therapy of de novo ALL: Strategy of the Spanish PETHEMA group
  JMR Ribera (Spain)
• 9.2 Current first-line trials from the French-Belgian-Swiss Group for Research on Adult ALL (GRAALL)
  HD Dombret (France)
• 9.3 CELL treatment approaches for de novo Ph- negative and Ph-positive ALL
  FF Folber (Czech Republic)
• 9.4 Standard therapy for young adults with Philadelphia-negative ALL in Sweden
  HH Hallböök (Sweden)
• 9.5 Current first line trials of the German Multicenter Study Group for Adult ALL (GMALL)
  N Gökbuget (Germany)
• 9.6 Optimization of the treatment of adults with acute lymphoblastic leukemia according to Polish Adult Leukemia Group (PALG)-ALL7 protocol
  S Giebel (Poland)

11:00 - 11:30 Coffee break & Poster viewing

11:30 - 12:30 DEBATE

Any role of SCT 5 years from now?

Chair: R Foà (Italy)

• Yes
  A Fielding (United Kingdom)
• No
  R Bassan (Italy)

12:30 - 13:00 Closing remarks

Burning questions for the next decade

Chair: N Gökbuget (Germany)

• R Foà (Italy)
• JM Ribera (Spain)
• D Hoelzer (Germany)
• A Fielding (United Kingdom)
• R Bassan (Italy)

13:00 - 14:00 Farewell lunch